Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

ClinicalTrials.gov ID: NCT02955550

Public ClinicalTrials.gov record NCT02955550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma

Study identification

NCT ID
NCT02955550
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Celularity Incorporated
Industry
Enrollment
15 participants

Conditions and interventions

Interventions

  • PNK-007 Biological
  • rhIL-2 Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 4, 2017
Primary completion
Jul 9, 2018
Completion
Jun 3, 2019
Last update posted
Jul 21, 2020

2017 – 2019

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
University of Minnesota Minneapolis Minnesota 55455
Washington Univ School of Medicine Siteman Cancer Center St Louis Missouri 63110
University of Nebraska Medical Center Omaha Nebraska 68198-6805
Hackensack University Medical Center Hackensack New Jersey 07601
Roswell Park Cancer Institute Buffalo New York 14263
Mt. Sinai School of Medicine New York New York 10029
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02955550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 21, 2020 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02955550 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →